3 recruiting, 1 withdrawn. 4 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Recruiting 3, Withdrawn 1 |
| Phase 2 | 1 | Recruiting 1 |
Follow Alveolar Soft Part Sarcoma: new trials by email Literature Review of Alveolar Soft Part Sarcoma trials Research Report on Alveolar Soft Part Sarcoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory GPNMB-Expressing Solid Tumours Fludarabine, Cyclophosphamide, GCAR1 - Alveolar Soft Part Sarcoma, Renal Cell Carcinoma | Phase 1 | Recruiting | Canadian Cancer Trials Group | 30 | 2026-08-30 | 2026-11-12 |
| Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors Miltenyi CliniMACS Prodigy ® system, Zoledronic acid - Neuroblastoma, Rhabdomyosarcoma | Phase 1 / Phase 2 | Recruiting | University of Florida | 27 | 2026-02-11 | 2026-06-30 |
| AB122 Platform Study AB122, TAS-116, TAS-120 - Advanced or Metastatic Solid Tumor, Pancreatic Ductal Adenocarcinoma | Phase 1 | Recruiting | Taiho Pharmaceutical Co., Ltd. | 917 | 2021-06-01 | 2026-08-05 |
| Selinexor in Combination With Ixazomib for the Treatment of Advanced Sarcoma Selinexor, Ixazomib - Liposarcoma, Malignant Peripheral Nerve Sheath Tumors | Phase 1 | Withdrawn | Matthew Ingham | 2020-11-01 | 2020-11-27 |
Sarcoma, Alveolar Soft Part (4) · Sarcoma (2) · Sarcoma, Ewing (2) · Biliary Tract Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Renal Cell (1) · Chordoma (1) · Colorectal Neoplasms (1) · Desmoplastic Small Round Cell Tumor (1) · Esophageal Neoplasms (1) · Head and Neck Neoplasms (1) · Liposarcoma (1) · Myoepithelioma (1) · Neoplasm Metastasis (1) · Nerve Sheath Neoplasms (1)
Neoplasms (4) · Neoplasms by Histologic Type (4) · Neoplasms, Connective and Soft Tissue (4) · Neoplasms, Muscle Tissue (4) · Neoplasms by Site (3) · Female Urogenital Diseases (2) · Female Urogenital Diseases and Pregnancy Complications (2) · Kidney Diseases (2) · Kidney Neoplasms (2) · Male Urogenital Diseases (2) · Neoplasms, Bone Tissue (2) · Neoplasms, Connective Tissue (2) · Neoplasms, Glandular and Epithelial (2) · Neoplasms, Nerve Tissue (2) · Nervous System Diseases (2)
130-nm albumin-bound paclitaxel (1) · 4-(2-fluoro-4-((((2-phenylacetyl)amino)thioxomethyl)amino)phenoxy)-7-methoxy-N-methyl-6-quinolinecarboxamide (1) · Bevacizumab (1) · Carboplatin (1) · Cisplatin (1) · Cyclophosphamide (1) · Fluorouracil (1) · Gemcitabine (1) · Ramucirumab (1) · TAS-116 (1) · Zoledronic Acid (1) · fludarabine (1) · futibatinib (1) · ixazomib (1) · selinexor (1)
Canadian Cancer Trials Group (1) · Matthew Ingham (1) · Taiho Pharmaceutical Co., Ltd. (1) · University of Florida (1)
United States (2) · Canada (1) · Japan (1)
Jordan Milner, MD (1) · Matthew Ingham, MD (1) · Mona Shafey (1)